Hologic, Inc. $HOLX Shares Purchased by Citigroup Inc.

Citigroup Inc. lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,307,113 shares of the medical equipment provider’s stock after acquiring an additional 25,128 shares during the period. Citigroup Inc. owned approximately 0.59% of Hologic worth $85,171,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Capital Investment Counsel Inc increased its holdings in Hologic by 2.6% in the 2nd quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock valued at $379,000 after purchasing an additional 150 shares in the last quarter. Greenleaf Trust boosted its position in shares of Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock worth $233,000 after buying an additional 173 shares during the period. Savant Capital LLC grew its stake in shares of Hologic by 1.2% in the second quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock valued at $1,278,000 after buying an additional 232 shares in the last quarter. First American Bank raised its holdings in shares of Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock valued at $1,870,000 after buying an additional 245 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its position in Hologic by 1.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,788 shares of the medical equipment provider’s stock worth $964,000 after acquiring an additional 246 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

HOLX opened at $74.11 on Wednesday. The company has a market capitalization of $16.48 billion, a P/E ratio of 30.75, a PEG ratio of 2.54 and a beta of 0.65. The company has a 50-day moving average of $70.06 and a 200-day moving average of $66.04. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $80.31.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $1.01 earnings per share. Equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Stephens downgraded shares of Hologic from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $78.00 to $76.00 in a research report on Wednesday, October 22nd. Morgan Stanley raised their price target on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. BTIG Research reiterated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Finally, Argus lifted their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.77.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.